Related Experiment Videos
Olsalazine-induced lupus syndrome
I Gunnarsson1, E Pettersson, S Lindblad
1Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden.
Scandinavian Journal of Rheumatology
|January 1, 1997
Summary
A patient developed severe systemic lupus erythematosus (SLE) after switching from sulphasalazine to olsalazine for ulcerative colitis. Discontinuing olsalazine led to symptom resolution, suggesting a drug-induced lupus.
Area of Science:
- Pharmacology
- Rheumatology
- Gastroenterology
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Sulphasalazine and olsalazine are aminosalicylate derivatives used to treat UC.
- Drug-induced hypersensitivity reactions can occur with long-term medication use.
Observation:
- A 73-year-old woman with a history of UC developed cutaneous manifestations during long-term sulphasalazine therapy.
- Following a therapeutic switch to olsalazine, the patient presented with severe systemic lupus erythematosus (SLE) involving multiple organ systems.
Findings:
- The patient's SLE symptoms and associated serological abnormalities significantly improved after olsalazine discontinuation.
- This clinical course strongly suggests a causal link between olsalazine and the development of drug-induced SLE.
Implications:
- Olsalazine should be considered as a potential trigger for drug-induced lupus in susceptible individuals.
- Careful patient monitoring for autoimmune phenomena is warranted during aminosalicylate therapy for inflammatory bowel disease.
- This case highlights the importance of medication history in diagnosing and managing complex autoimmune presentations.